Advertisement
Advertisement
EPRX
Eupraxia Pharmaceuticals Inc. Common Stock
6.77
USDSponsored
+0.11
+1.65%
Aug 07, 15:59 UTC -4
Closed
After-Market
6.83
+0.06
+0.81%
EPRX Earnings Reports
Positive Surprise Ratio
EPRX beat 8 of 17 last estimates.
47%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Eupraxia Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Aug 07, 2026, EPRX reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.23 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Eupraxia Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Eupraxia Pharmaceuticals Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Eupraxia Pharmaceuticals Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Eupraxia Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Eupraxia Pharmaceuticals Inc. Common Stock's next earnings report?
Based on --
analysts, Eupraxia Pharmaceuticals Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement